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Abstract
Here we present the case of a 57-years
old patient affected by hemophagocytic
lymphohistiocytosis (HLH), a rare disease
characterized by an uncontrolled immune
activation, resulting in clinical and bio-
chemical manifestations of extreme inflam-
mation. In a previous hospitalization, the
patient showed fever, hepato-splenomegaly,
pancytopenia, hyperferrtitinemia, lym-
phadenopathy and cholestasis. No diagnosis
was done, however, he totally recovered
after splenectomy. Eight months later, he
relapsed, showing also hypofibrinogene-
mia, hypertriglyceridemia, hemophagocytic
signs in bone marrow, cholestatic jaundice,
high LDH and high PT-INR. Interestingly,
he presented increased levels of amylase
and lipase in absence of radiologic signs of
pancreatitis. He was treated with
Dexamethasone and Cyclosporine accord-
ing to HLH-2004 guidelines. The clinical
and biochemical manifestations disap-
peared in a few weeks, but he was newly
hospitalized for lower limbs hypotonia
caused by a hemophagocytic lesion of the
cauda equina and lumbar cord. The death
occurred in a few days, despite the immuno-
suppressive treatment.
Introduction
The histiocytic cells or macrophages are
innate immune cells characterized by a
strong phagocytic activity, deriving from
maturation and tissue migration of the cir-
culating monocytes of bone marrow
monoblastic origin. The proliferative disor-
ders involving histiocytes or histiocyte-like
cells are named histiocytic syndromes.
Different classifications have tried to delin-
eate these different and complex entities.
The Komp-Perry classification in 1991,1
considered the histiocytosis of Langherans
cells in the first class, the hemophagocytic
syndromes in the second one and the malig-
nant histiocytosis including the histiocytic
lymphoma in the third one. Similar was the
more recent Favara classification (1997)2
that distinguished the histiocytic disorders
into histiocytosis of dendritic cells, histio-
cytosis of macrophages and malignant ones,
according to the specific immunohisto-
chemical features. A further clarification is
needed for the true histiocytic lymphoma
that appeared also in Rappaport classifica-
tion of lymphomas in 1966,3 but according
to the WHO classification (2008),4 the last
currently accepted, it is no longer recog-
nized as an isolated entity and it is included
in B diffuse large cell or anaplastic T lym-
phomas. In the context of the histiocytic
disorders involving the monocyte-
macrophage line cell, a rare and often lethal
disease is the hemophagocytic lymphohisti-
ocytosis (HLH), characterized by a cytokine
explosion secondary to an excessive but
ineffective immune response with a conse-
quent abnormal activation of CD8+ T lym-
phocytes, resulting into INFɣ release,
monocyte-macrophages activation and
infiltration in tissues. The result is multior-
gan failure. It is distinguished by a primitive
form, typical of childhood (familiar) and a
secondary form related to infections,
autoimmune diseases or neoplasms (lym-
phomas and solid tumors). However, in a
significant percentage of HLH in adulthood
no cause is identified (idiopathic form). In
2004, clinical and laboratory criteria neces-
sary for HLH diagnosis and a recommended
therapeutic protocol have been proposed5.
Here we describe the case of an adult
patient with the diagnostic criteria for HLH
characterized by a very aggressive and neo-
plastic-like behavior.
Case Report
A 57 years old man was hospitalized in
February 2015 in our Internal Medicine
Division due to fever and pancytopenia. He
was in a healthy condition until one year
before (February 2014) when he was hospi-
talized for unknown origin fever (FUO). On
that occasion the total-body computerized
axial tomography (CAT) showed a medi-
astinum lymphadenopathy, a hepatomegaly
with normal bile ducts and a splenomegaly
(maximum diameter 18 cm). The bone mar-
row histology detected an aspecific mild tri-
linear hyperplasia, signs of dyserythro-
poiesis, slight excess of lymphoid cells with
cytotoxic phenotype; the axillary lymph
node biopsy showed a fatty involution.
Because of worsening pancytopenia and
cholestasis appearance he underwent
splenectomy and liver biopsy. Histological
exams showed a splenic tissue with a T
cytotoxic lymphocyte proliferation without
immunohistochemical and morphological
malignancy signs, while the hepatic
parenchyma was characterized by plasma-
cells and eosinophils, areas of spotty necro-
sis and Mallory bodies. After splenectomy
and a therapy based on large spectrum
antibiotics and immunoglobulins, in a few
weeks the patient made a total recovery,
when the fever disappeared and the blood
examinations normalized. Eight months
later (February 2015), at admission to our
Division he presented a blood pressure of
100/50 mmHg, a heart frequency of 82 per
minute, body temperature 38.7°C, mucocu-
taneous pallor, a diffused reduction of
vesicular murmur and the liver was palpa-
ble 3 cm from costal margin. Blood tests
were as follow: hemoglobin (Hb) 9.6 g/dL,
red blood cells (RBC) 3.25×106/µL, white
blood cells (WBC) 2.11×103/µL with 2.8%
of neutrophils and 87% of lymphocytes,
platelets (PLT) 22×103/µL, ferritin 17813
ng/mL (n.v. 8-252 ng/mL), albumin 2.3
g/dL, LDH 541 U/L (n.v. 84-246 U/L), total
bilirubin (T-bil) 2 mg/dL (direct 1.43
mg/dL), AST 108 U/L (n.v. 15-37 U/L),
ALT 130 U/L (n.v. 12-78 U/L), gammaglu-
tamyltranspeptidase (GGT) 109 U/L (n.v. 5-
55 U/L), alkaline phosphatase (ALP) 204
U/L (n.v. 50-136 U/L), PT-INR 1.15, aPTT
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1.49 Ratio, fibrinogen 115 mg/dL (n.v. 200-
400 mg/dL), d-dimers 3.99 ug/mL (n.v.
<0.5 ug/mL), reactive C-protein 55.4 mg/L
(n.v. <2.9 mg/L), amylase 148 U/L (n.v. 8-
53 U/L), lipase 2201 U/L (n.v. 73-393 U/L),
creatinine 1.07 mg/dL, estimated glomeru-
lar filtration rate (eGFR) 77 mL/min,
triglycerides 530 mg/dL. Every serological
and cultural test for virus, bacteria and par-
asites were negative. A lymphadenomegaly
at hepatic hilum and in peripancreatic zone
was the lonely CAT alteration. Therefore, a
bone marrow biopsy was performed, while
the patient appeared icteric (T-bil 18 mg/dL,
mostly direct), with a continuous feverover
38.5°C, and he presented a further reduction
of leucocytes to 1.2×103/µL, a risingferritin
to 28545 ng/mL, a worsening coagulation
parameters, and persistently high enzymes
of cholestasis and pancreatitis. The histo-
logical analysis described an interstitial
infiltration of histiocytes CD 68 ++ with
some hemophagocytosis signs.   
Consequently, the diagnosis of the HLH
was made and the patient started therapy
according to guidelines HLH-2004 with
Etoposide exclusion because of bone mar-
row hypocellularity, and in addition to large
spectrum antiobotics and immunoglobulins
at 400 mg/kg/die for 5 days. In the follow-
ing weeks the fever disappeared and the
patient improved from a clinical and hema-
tochemical point of view. In 8 weeks the
patient had totally recovered and he contin-
ued with maintenance therapy. After about 6
months he was submitted to our Unit with
paresthesias, hypotonia and muscle atrophy
of the lower limbs, predominantly the left
side, which evolved to paresis. On admis-
sion, blood tests showed only hyperfer-
ritinemia (5189 ng/mL). The CAT, com-
pared to the previous one, presented a
numerical and volumetric increase in the
lateral cervical lymphadenopathy, with evi-
dence of lymph nodes also in hepatic hilum,
peripancreatic and left supraclavicular
regions. PET-CAT showed a diffuse hyper-
accumulation of the radiopharmaceutical in
the liver, laterocervical and retro-clavicular
left region, hepatic hilum, and bone mar-
row. Therefore, the patient underwent exci-
sional biopsy of lateral cervical left lymph
node, that showed a structure subverted by
widespread proliferation of histiocytic ele-
ments CD68+, comprising focal aspects of
hemophagocytosis and many T-lympho-
cytes (Figure 1). The brain magnetic-reso-
nance-imaging (MRI) was negative for
injury, while spine MRI showed pathologi-
cal tissue at the level of the cauda equina
and leptomeninge covering the spinal cord
cone, mainly in the vertebral body L3, and
intervertebral space L2-L3 (Figure 2).
These findings were interpreted as histio-
cytic infiltration of the lumbar subarachnoid
space. The bone marrow biopsy described a
hypercellular bone marrow with a zonal
increase, in the interstitial region, of the
proportion of histiocytes, positive for CD68
(PGM1), some of large size with aspects of
erythrophagocytosis (Figure 3). During the
hospital stay, despite treatment, the patient
presented a recurrence of all laboratory
abnormalities of previous hospitalization
and a rapid clinical deterioration as well as
high fever, jaundice, stupor and death.
Discussion and Conclusions
The HLH in adults is more frequently a
secondary form, while the primary form is
typical of childhood linked to genetic muta-
tions. Infective, autoimmune and neoplastic
causes were excluded in this case, indeed
we could only suppose this form was an
idiopathic hemophagocytic lymphohistio-
cytosis, since the unavailability of genetic
examinations. Currently, the diagnosis cri-
teria are defined in HLH-2004 guidelines as
5 positives out of 8 possibilities: i) fever; ii)
splenomegaly; iii) cytopenia affecting ≥2 of
3 lineages in the peripheral blood:
Hemoglobin (<90 g/L), Platelets
(<100×109/L), Neutrophils (<1.0×109/L); iv
hypertriglyceridemia and/or hypofibrino-
genemia (triglycerides ≥265 mg/dL; fib-
rinogen ≤1.5 g/L); v) hemophagocytosis in
bone marrow, spleen or lymph nodes; vi)
low or absent NK-cell activity, vii) ferritin
≥500 microgram/L; viii) soluble CD25
≥2400 U/mL.5 Despite the unavailability of
our hospital laboratory to measure sCD25
and NK-cell activity, our patient showed 6
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Figure 1. Lymph node (hematoxylin and eosin): a dense infiltrate of histiocytes including
small reactive lymphocytes.
Figure 2. Magnetic resonance imaging of
spinal cord (T2 image): pathological tis-
sue infiltrating cauda equine, mainly in
the vertebral body of L3, and interverte-










positive criteria (fever, splenomegaly,
cytopenia, hypertriglyceridemia and
hypofrinogenemia, hemophagocytosis
signs). Furthermore, the patient showed
other clinical and biochemical manifesta-
tions that are very common in HLH of
adults such as cholestasis, high PT INR and
high LDH, although they are still not
included in guidelines.6 Therefore, it could
be useful considering new diagnose criteria,
also in addition to those proposed by Delphi
study and H score.7,8 Only a few hemo-
phagocytosis signs were detectable in
patient’s bone marrow, in spite of the wide
and aggressive clinical manifestation.
Accordingly, we agree that the bone mar-
row aspect should not be considered as a
gold standard, because the typical hemo-
phagocytosis signs predominantly appear in
the more advanced disease stages, and they
are absent in about 40% of cases.9,10
Moreover, this case presented two clinical
peculiarities. The first one is the presence of
raised amylase and lipase with demonstrat-
ed absence of radiological pancreatitis signs
and bile ducts dilation and/or obstruction by
Magnetic resonance cholangiopancreatog-
raphy (MRCP) and Endoscopic retrograde
cholangiopancreatography (ERCP). This
pancreatic alteration persisted until the
beginning of immunosuppressive therapy.
The HLH is a systemic syndrome thus
every tissue and organ may theoretically be
involved by histiocyte infiltration.
Therefore, we think that patient’s raised
pancreatic enzymes could be the conse-
quence of mild pancreatic ducts inflamma-
tion with a mechanism similar to the more
typical hepatic involvement. HLH cases
with pancreatitis are very rare and only one
adult case is described with radiologic signs
of pancreatitis though correlated to the pres-
ence of ulcerative colitis.11,12 The second
clinical characteristic was the finding of a
large histiocyte infiltration in the spinal
cord, which determined left lower limb
paresis with a progressive muscular atro-
phy. The HLH usually involves central
nervous structures as the periventricular
substance, thalamus and basal ganglia,13
leading to neurological symptoms such as
conscience alterations, meningism, focal
neurological deficits and epilepsy. Rare
cases of HLH are described with spinal cord
involvement and probably no case is
described with spinal cord involvement and
brain savings.14,15 Therefore, diagnosing the
HLH in adults may be arduous since the
large clinical manifestations variety and the
restricted number of diagnosis criteria; fur-
thermore deciding an appropriate therapy is
very difficult, considering the absence of
guidelines for adults. There are only case
series of adult patients treated with various
regimens mostly based on cyclosporine,
dexamethasone, etoposide and more recent-
ly on stem cell transplantation, reporting a
poor response and a high mortality.16-19
Although no diagnosis was done during
patient’s first manifestation, the patient
totally recovered after splenectomy and
without any immunosuppressive treatment.
In fact, the splenectomy has been suggested
as an alternative treatment in idiopathic
HLH of adults not responsive to standard
therapy.20 The patient showed a relapse
after splenectomy and so he underwent a
treatment based on the HLH-2004 protocol,
a prospective study of the Histiocyte
Society conducted on pediatric patients
with no history of immunosoppression or
malignancy.5 Etoposide infusion was
excluded for bone marrow hypocellularity,
while cyclosporine and dexamethasone
were administered with an 8-week induc-
tion and following maintenance therapy.
However, the patient relapsed after 6
months, the high dexamethasone dosage
was useless and the death occurred in a few
days. This case report demonstrates that
HLH in adults can appear in an unusual
way, thus a diagnosis criteria revision is
needed to facilitate disease recognition and
anticipate the treatment. In addition, further
studies are necessary to understand patho-
genesis and to choose the optimal treatment
in adults. As it has been described in the
introductive section, currently HLH is not
considered a malignant histiocytosis.
However, HLH prognosis is very poor with
a high rate of relapse and, although in this
syndrome histiocytic cells have no cellular
atypia or other malignant aspects, their
behaviour is aggressive. Therefore, we
agree to treat HLH aggressive forms with
lymphoma-type chemotherapies.
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